Published in Proc Natl Acad Sci U S A on November 09, 1999
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun (2011) 3.23
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci (2009) 2.00
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.91
Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol (2010) 1.88
Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci (2001) 1.77
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci (2009) 1.67
The synucleins. Genome Biol (2001) 1.65
The function of α-synuclein. Neuron (2013) 1.63
α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.62
Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol (2003) 1.53
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol (2007) 1.52
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol (2000) 1.52
1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci U S A (2007) 1.51
Residual structure, backbone dynamics, and interactions within the synuclein family. J Mol Biol (2007) 1.43
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J Cell Biol (2004) 1.39
Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet (2009) 1.37
Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience (2008) 1.29
Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol (2001) 1.28
Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathol (2011) 1.26
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain (2011) 1.22
The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal (2010) 1.16
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol (2007) 1.08
Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res (2008) 1.08
Molecular anatomy of the hair cell's ribbon synapse. J Neurosci (2010) 1.08
A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun (2010) 1.05
Secondary structure and dynamics of micelle bound beta- and gamma-synuclein. Protein Sci (2006) 1.04
Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. Neurobiol Dis (2012) 1.01
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener (2010) 1.00
Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol (2003) 1.00
The Synaptic Function of α-Synuclein. J Parkinsons Dis (2015) 0.98
Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. J Neurosci (2014) 0.96
Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol (2010) 0.95
Effect of pseudorepeat rearrangement on alpha-synuclein misfolding, vesicle binding, and micelle binding. J Mol Biol (2009) 0.95
α-synuclein induced synapse damage is enhanced by amyloid-β1-42. Mol Neurodegener (2010) 0.93
Parkinson's disease as a result of aging. Aging Cell (2015) 0.92
The occurrence of aging-dependent reticulon 3 immunoreactive dystrophic neurites decreases cognitive function. J Neurosci (2009) 0.89
Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies. Parkinsons Dis (2012) 0.87
The Progressive BSSG Rat Model of Parkinson's: Recapitulating Multiple Key Features of the Human Disease. PLoS One (2015) 0.86
Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity. Dis Model Mech (2014) 0.86
New α- and γ-synuclein immunopathological lesions in human brain. Acta Neuropathol Commun (2014) 0.85
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem (2016) 0.85
Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background. Eur J Neurosci (2011) 0.84
Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death Dis (2015) 0.84
Quantitative neuropathology associated with chronic manganese exposure in South African mine workers. Neurotoxicology (2013) 0.84
Effect of nanomolar concentrations of sodium dodecyl sulfate, a catalytic inductor of alpha-helices, on human calcitonin incorporation and channel formation in planar lipid membranes. Biophys J (2004) 0.84
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol Dis (2014) 0.83
Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein. J Neurochem (2008) 0.83
Critical role of calpain in spinal cord degeneration in Parkinson's disease. J Neurochem (2013) 0.82
Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein. Mol Brain (2012) 0.82
Munc18-1 is a molecular chaperone for α-synuclein, controlling its self-replicating aggregation. J Cell Biol (2016) 0.81
Role of gamma-synuclein in microtubule regulation. Exp Cell Res (2010) 0.81
A pH Dependent Switch Promotes β-Synuclein Fibril Formation via Glutamate Residues. J Biol Chem (2017) 0.81
Can BACE1 inhibition mitigate early axonal pathology in neurological diseases? J Alzheimers Dis (2014) 0.80
Novel subcellular localization for α-synuclein: possible functional consequences. Front Neuroanat (2015) 0.80
Gamma-synuclein pathology in amyotrophic lateral sclerosis. Ann Clin Transl Neurol (2014) 0.80
Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson's Disease. Int J Mol Sci (2015) 0.79
Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies? J Neurol (2009) 0.79
Identifying Tmem59 related gene regulatory network of mouse neural stem cell from a compendium of expression profiles. BMC Syst Biol (2011) 0.79
Retrograde Axonal Degeneration in Parkinson Disease. J Parkinsons Dis (2016) 0.79
Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS One (2013) 0.78
A network view on Parkinson's disease. Comput Struct Biotechnol J (2013) 0.78
Neuroprotective effects of protocatechuic aldehyde against neurotoxin-induced cellular and animal models of Parkinson's disease. PLoS One (2013) 0.78
Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Mol Cell Proteomics (2016) 0.77
Compromised axonal functionality after neurodegeneration, concussion and/or traumatic brain injury. J Comput Neurosci (2014) 0.77
Anterior-posterior cerebral blood volume gradient in human subiculum. Hippocampus (2014) 0.77
Diversity of mitochondrial pathology in a mouse model of axonal degeneration in synucleinopathies. Oxid Med Cell Longev (2013) 0.77
Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathies. Int J Mol Sci (2012) 0.77
Evaluation of the synuclein-γ (SNCG) gene as a PPARγ target in murine adipocytes, dorsal root ganglia somatosensory neurons, and human adipose tissue. PLoS One (2015) 0.76
Bridging molecular genetics and biomarkers in lewy body and related disorders. Int J Alzheimers Dis (2011) 0.76
Cell-specific post-transcriptional regulation of γ-synuclein gene by micro-RNAs. PLoS One (2013) 0.76
Transcriptional regulation of the beta-synuclein 5'-promoter metal response element by metal transcription factor-1. PLoS One (2011) 0.76
Differential involvement of the gamma-synuclein in cognitive abilities on the model of knockout mice. BMC Neurosci (2013) 0.76
cAMP-Inhibits Cytoplasmic Phospholipase A₂ and Protects Neurons against Amyloid-β-Induced Synapse Damage. Biology (Basel) (2015) 0.75
Identification of Multiple QTLs Linked to Neuropathology in the Engrailed-1 Heterozygous Mouse Model of Parkinson's Disease. Sci Rep (2016) 0.75
α-Synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2. Biomolecules (2015) 0.75
Functionality and Robustness of Injured Connectomic Dynamics in C. elegans: Linking Behavioral Deficits to Neural Circuit Damage. PLoS Comput Biol (2017) 0.75
Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies. Biomolecules (2015) 0.75
eSNPO: An eQTL-based SNP Ontology and SNP functional enrichment analysis platform. Sci Rep (2016) 0.75
Reducing synuclein accumulation improves neuronal survival after spinal cord injury. Exp Neurol (2016) 0.75
Neuromythology of Manganism. Curr Epidemiol Rep (2015) 0.75
Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism. F1000Res (2017) 0.75
Reaction time impairments in decision-making networks as a diagnostic marker for traumatic brain injuries and neurological diseases. J Comput Neurosci (2017) 0.75
Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell Mol Life Sci (2017) 0.75
Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Res (2017) 0.75
Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease. Sci Rep (2017) 0.75
Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? Dis Model Mech (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature (1995) 7.48
Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell (1985) 6.06
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1993) 3.73
Identification of two distinct synucleins from human brain. FEBS Lett (1994) 3.61
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res (1997) 2.05
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
Pathology and biology of the Lewy body. J Neuropathol Exp Neurol (1993) 1.99
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ (1998) 1.92
Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology (1991) 1.69
Synapsin I in nerve terminals: selective association with small synaptic vesicles. Science (1984) 1.67
A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem (1993) 1.49
Ubiquitin and microtubule-associated protein tau immunoreactivity each define distinct structures with differing distributions and solubility properties in Alzheimer brain. Proc Natl Acad Sci U S A (1988) 1.41
Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol (1999) 1.40
Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest (1998) 1.32
Identification, localization and characterization of the human gamma-synuclein gene. Hum Genet (1998) 1.27
Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol (1994) 1.27
Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet (1998) 1.14
Pathobiology of the Lewy body. Adv Neurol (1999) 1.05
Human synaptic proteins with a heterogeneous distribution in cerebellum and visual cortex. Brain Res (1993) 1.00
Analysis of the alpha-synuclein G209A mutation in familial Parkinson's disease. Lancet (1998) 1.00
Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann Neurol (1998) 0.99
Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics (1995) 0.98
Block of transmitter release by botulinum C1 action on syntaxin at the squid giant synapse. Proc Natl Acad Sci U S A (1997) 0.98
The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. Genomics (1995) 0.96
Cloning and characterization of the cDNA encoding a novel brain-specific 14-kDa protein. J Neurochem (1992) 0.95
Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology (1998) 0.94
The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics (1995) 0.94
Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann Neurol (1997) 0.94
Standardization of various applications of methacrylate embedding and silver methenamine for light and electron microscopy immunocytochemistry. Histochemistry (1984) 0.92
Frontotemporal dementia: neuropil spheroids and presynaptic terminal degeneration. Ann Neurol (1998) 0.90
The synaptic vesicle and its targets. Neuroscience (1995) 0.89
Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). Hum Mol Genet (1998) 0.87
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell (1992) 2.80
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. EMBO J (1987) 2.72
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J Neurosci (1992) 2.50
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci (1998) 2.43
Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem (2000) 2.42
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest (1992) 2.30
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A (1999) 2.26
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med (1997) 2.15
Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci (1987) 2.15
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem (1999) 2.13
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13
Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem (1997) 2.12
Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology (2005) 2.10
Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology (2007) 2.09
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A (1996) 2.08
Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem (2000) 2.02
Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen (2008) 2.00
Pathological changes in olfactory neurons in patients with Alzheimer's disease. Nature (1989) 2.00
Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J Virol (1985) 2.00
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A (1993) 1.99
Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol (1997) 1.98
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
NTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell. J Neurosci Res (1993) 1.97
Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol (1997) 1.95
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ (1998) 1.92
Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A (1999) 1.91
Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol (1998) 1.89
Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol (1998) 1.89